Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Endometrial Neoplasms 5Anorexia 3Weight Loss 2Endometrial Hyperplasia 2Cachexia 2Breast Neoplasms 2Body Weight 2Squamous Intraepithelial Lesions 1Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Body Weight Changes 1

Interventions

Gemcitabine 153Fluorouracil 45Capecitabine 45130-nm albumin-bound paclitaxel 43Oxaliplatin 42Albumin-Bound Paclitaxel 39Leucovorin 31Erlotinib Hydrochloride 30pembrolizumab 23Radiotherapy 22Irinotecan 22Radiosurgery 20Bevacizumab 19Docetaxel 17Cyclophosphamide 17Taxes 13Cisplatin 13Cetuximab 13folfirinox 12Nivolumab 11Surgical Procedures, Operative 7Paclitaxel 7Ipilimumab 7dehydroftorafur 6Standard of Care 6Radiation 6Magnetic Resonance Spectroscopy 6spartalizumab 5ruxolitinib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pancreatic Neoplasms × Megestrol Acetate × Clear all
NCT00637728 2016-06-23

Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

Par Pharmaceutical, Inc.

Phase 3 Terminated
5 enrolled 8 charts
GastrointestinalThoracic

Anorexia, Body Weight, Cachexia, Lung Neoplasms, Pancreatic Neoplasms, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡